Everolimus vs. Temsirolimus for Advanced Renal Cell Carcinoma: Use and Use of Resources in the US Oncology Network
Authors:
- Nicholas J. VogelzangNVNicholas J. Vogelzang
- Menaka BhorMBMenaka Bhor
- Zhimei LiuZLZhimei Liu
- Rahul DhandaRDRahul Dhanda
- Thomas E. HutsonTHThomas E. Hutson
- 1 June 2013
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 11 (2) , 115-120
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Second-line therapy for refractory renal-cell carcinomaCritical Reviews in Oncology/Hematology, 2012
- Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling ParadigmMolecular Cancer Therapeutics, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Managing Refractory Metastatic Renal Cell Carcinoma: A RECORD Spinning on a Tilted AXISClinical Genitourinary Cancer, 2011
- Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical EvidenceThe Oncologist, 2011
- Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend AnalysisEuropean Urology, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell CarcinomaSeminars in Oncology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007